intradermal injection of CADI-05

Phase 1Biologic

intradermal injection of CADI-05 is one of 57 biologic programs targeting Head and Neck Squamous Cell Carcinoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Head and Neck Squamous Cell CarcinomaNot yet recruiting

Head and Neck Squamous Cell CarcinomaPhase 1

Not yet recruiting

Competition

Competitive Landscape

113 competitors in Head and Neck Squamous Cell Carcinoma

#DrugCompanyPhaseTrials

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

36 2

Erbitux

IImclone

Phase 3

27 3

Beyfortus

BeiGene

Phase 3

8 4

Imfinzi

AstraZeneca

Phase 3

6 5

Taxotere

AAvyxa

Phase 3

17 6

Ibrance

Pfizer

Phase 3

4 7

Tuoyi

CCoherus Oncology, Inc.

Phase 3

6 8

Adrucil

EElorac, Inc.

Phase 3

4 9

Gilotrif

Boehringer Ingelheim

Phase 3

4 10

Theraplaza

BBiotech Pharmaceutical Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Not yet recruiting

Head and Neck Squamous Cell Carcinoma

NCT07455032

Clinical

Trials by Indication[1]

Head and Neck Squamous Cell Carcinoma1 trial

Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell Carcinomas

Not yet recruiting·FFox Chase Cancer Center·Phase 1·NCT07455032·22 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for intradermal injection of CADI-05. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — intradermal injection of CADI-05 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for intradermal injection of CADI-05. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fox Chase Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: FFox Chase Cancer Center

intradermal injection of CADI-05

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Head and Neck Squamous Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News